Tetra Bio-Pharma Announces Closing of Bought Deal Financing – Yahoo Finance

TBP.V) (TBPMF), is pleased to announce it has closed its short form prospectus offering, on a bought deal basis. A total of 29,245,300 units (the “Units“) of the Corporation were sold at a price of $0.53 per Unit, for aggregate gross proceeds of $15,500,009 (the “Offering“).

The Corporation intends to use the net proceeds from the Offering to continue the development of its clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers, and for working capital and general corporate purposes.

TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

www.tetrabiopharma.com

Story continues